GlassScriptPhysician profile
Marie Jo Borres
NPI 1336698091
$4,266.39
in general payments reported to CMS, 2019-2025
17 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $680 · 2022: $1,540 · 2023: $1,347 · 2024: $597 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,030 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,030.12 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,166.34 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $550.66 | 2022-2024 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $327.69 | 2022-2023 | Jardiance, Synjardy |
| Lilly USA, LLC | $269.62 | 2022-2023 | Emgality, Reyvow, Mounjaro |
| Novo Nordisk INC | $237.97 | 2021 | |
| Ironwood Pharmaceuticals, INC | $136.55 | 2022 | |
| Gilead Sciences, INC. | $121.83 | 2023 | Epclusa |
| Glaxosmithkline, LLC. | $109.10 | 2023 | Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.43 | 2022 | |
| Merck Sharp & Dohme LLC | $67.66 | 2022 | |
| Smith+Nephew, INC. | $61.25 | 2024-2025 | Grafix Pl |
| Kerecis Limited | $40.56 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Redhill Biopharma INC. | $33.50 | 2023 | Talicia, Aemcolo, Movantik |
| Exact Sciences Corporation | $24.86 | 2024 | Cologuard Collection Kit |
| Amgen INC. | $24.49 | 2024 | Repatha, Otezla |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Solventum Corporation | $16.86 | 2025 | Promogran Prisma |
| Genentech USA, INC. | $6.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marie Jo Borres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.